In addition to the Melbourne and Sydney mid-year shareholder briefings, Noxopharm Limited now invites shareholders and interested parties to attend a Company briefing on:
• The Company’s formal clinical trial program
• A NOX66 compassionate use scheme for rare cancers and
cancers where patients have no access to formal studies
• The Company’s expanding non-oncology drug program.
Fior further information please download PDF attached:
Download this document
